Objective To investigate the clinical efficacy of Shenqi Fuzheng injection and chemotherapy in elderly patients with non-small cell lung cancer(NSCLC),and to observe its effect on immune function and serum tumor markers of carcino embryonie antigen(CEA),carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment(CYFRA21-1)and neuronspecific enolase(NSE).Methods 80 patients with NSCLC who were confirmed as non-small cell lung cancer were enrolled in the study.Among them,the control group received paclitaxel + carboplatin chemotherapy,40 patients; the treatment group received Shenqi Fuzheng injection on the basis of the control group,40 cases.The clinical curative effect was evaluated after four cycles of treatment and the adverse reactions were recorded.The scores of traditional Chinese medicine(TCM)syndrome before and after four cycles of treatment were evaluated,and the quality of life of the patients before and after treatment were evaluated by Karnofsky performance score(KPS).The immune function and tumor markers were measured before and after treatment.Results The total effective rate of the treatment group was 65.0％,which was significantly higher than that of the control group(42.5％,χ2=4.07,P=0.04).In the treatment group,the adverse reaction rate was 37.5％,significantly lower than 62.5％in the control group(χ2=5.00,P=0.02).The score of TCM syndrome in the two groups was significantly lower than that in the control group before treatment,and the KPS score was significantly higher than that in the control group before treatment,the score of TCM syndrome in the treatment group was significantly lower than that in the control group(P<0.05).After treatment,the immune function of patients in the treatment group compared with before treatment had no significant difference,while the control group after treatment of the immune function was significantly lower than before treatment,and compared with the treatment group(P<0.05).The two groups of patients after treatment of tumor markers decreased significantly,and the treatment group decreased significantly compared with the control group(P<0.05).Conclusion Supplemented with Shenqi Fuzheng injection in the treatment of elderly non-small cell lung cancer on the immune function of little effect,help to promote serum levels of serum tumor markers and clinical symptoms improved,reduce adverse reactions,improve clinical efficacy and quality of life.

Objective:To analyze the effects of apatinib on quality of life and immune function in older adult patients with advanced non-small cell lung cancer.Methods:A total of 187 older adult patients with advanced non-small cell lung cancer admitted to Taizhou Cancer Hospital from January 2017 to January 2021 were included in this study. They were divided into the control group ( n = 93) and the observation group ( n = 94). The control group was treated with carboplatin combined with pemetrexed and the observation group was treated with apatinib based on carboplatin and pemetrexed. Sign and symptoms remission was compared between the observation and control groups. The levels of tumor markers, immune function, and quality of life score were compared between the two groups before and after treatment. Results:Total remission rate in the observation group was significantly higher than that in the control group (88.30% vs. 69.89%, χ2 = 9.59, P < 0.05). After treatment, carbohydrate antigen 125, carbohydrate antigen 50, and carcinoembryonic antigen in the observation group were (16.25 ± 5.47) μg/L, (15.23 ± 3.27) μg/L and (5.91 ± 2.66) mg/L, respectively, which were significantly lower than (21.49 ± 6.61) μg/L, (19.11 ± 3.48) μg/L and (10.14 ± 2.73) mg/L in the control group ( t = 5.91, 7.86, 10.73, all P < 0.05). The percentage of CD3 + and CD4 + cells, and the ratio of CD4 +/CD8 + cells in the observation group were (69.34 ± 8.85)%, (38.15 ± 6.52)%, (1.40 ± 0.33), respectively, which were significantly higher than (64.51 ± 8.74)%, (33.55 ± 6.33)%, (1.23 ± 0.25) in the control group ( t = -3.75, -5.36, -3.97, all P < 0.05). Quality of life score was increased in each group ( P < 0.001). The amplitude of increase in quality of life score was greater in the observation group compared with the control group ( P < 0.001). Conclusion:Apatinib can effectively reduce the level of tumor markers and improve immune function in older adult patients with advanced non-small cell lung cancer and improve quality of life.

Objective To evaluate the curative effect of transcatheter arterial chemoembolization (TACE) combined with intensity modulated radiation therapy (IMRT) in treating advanced hepatocellular carcinoma (HCC),and to discuss the occurrence of adverse events.Methods A total of 59 patients with advanced HCC were enrolled in this study.The patients were randomly divided into TACE plus IMRT group (study group,n=30) and TACE group (control group,n=29).The early tumor response rate,progression free survival (PFS),median survival time (mST),and adverse reactions were analyzed.Results The early tumor response rate in the study group was 60.0％,which was significantly higher than 34.4％ in the control group (P=0.043).PFS of the study group was 260 days,which was remarkably higher than 195 days of the control group (P=0.006).The mST was 468 days in the study group,which was 431 days in the control group (P=0.195).In the study group,2 patients developed severe liver function damage,which was improved after active liver protection therapy for more than 20 days.Conclusion For the treatment of advanced HCC,TACE combined with IMRT can improve early tumor response rate and prolong PFS time,moreover,its adverse reactions can be well tolerated by patients.